STOCK TITAN

Sight Sciences to Report Third Quarter 2023 Financial Results on November 7, 2023

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings
Rhea-AI Summary
Sight Sciences, Inc. will report financial results for Q3 2023 on November 7th. The company's management will discuss the results during a conference call.
Positive
  • Investors can access a live and archived webcast of the conference call on the company's website.
Negative
  • None.

MENLO PARK, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients’ lives, today announced it will report financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 7, 2023. The company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.com, on the Investors page in the News & Events section. The webcast will be available for replay for at least 90 days after the event.

About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (“MIGS”) technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (“POAG”), the world’s leading cause of irreversible blindness. The Company’s TearCare System technology is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (“MGD”) when used in conjunction with manual expression of the meibomian glands, enabling office-based clearance of gland obstructions by physicians to address the leading cause of dry eye disease. The Company’s SION™ Surgical Instrument is a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

For more information, visit www.sightsciences.com.

OMNI and TearCare are registered trademarks of Sight Sciences.
SION is a trademark of Sight Sciences.

© 2023 Sight Sciences. All rights reserved.

Media contact
pr@SightSciences.com

Investor contact:
Philip Taylor
Gilmartin Group
415.937.5406
Investor.Relations@Sightsciences.com


FAQ

When will Sight Sciences report its financial results for Q3 2023?

Sight Sciences will report its financial results for Q3 2023 on November 7th.

How can investors listen to the conference call?

Investors can access a live and archived webcast of the conference call on Sight Sciences' website.

Will the webcast be available for replay?

Yes, the webcast will be available for replay for at least 90 days after the event.

Sight Sciences, Inc.

NASDAQ:SGHT

SGHT Rankings

SGHT Latest News

SGHT Stock Data

230.41M
50.31M
20.08%
50.9%
2.22%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
MENLO PARK